Your session is about to expire
← Back to Search
CAR-T Cell Therapy for Multiple Myeloma
Study Summary
This trial is testing a new cancer treatment involving genetically engineering a patient's own T cells to better attack their tumor. So far it is showing to be feasible and safe with preliminary signs of efficacy.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a condition that can be measured according to the study's guidelines.I have previously received a genetic cell therapy but not BCMA-directed bi-specific antibodies or ADC.My leukapheresis material is approved for use.My blood test results are within normal ranges.I can take care of myself and am up and about more than half of my waking hours.I haven't had chemotherapy or other cancer treatments except for LD chemotherapy in the last 2 weeks.I have had my own stem cell transplant within the last 6 weeks or have never had a stem cell transplant from a donor.I have MM, failed at least 2 treatments including specific drugs, and my disease is getting worse.I have not received any immunotherapy (except daratumumab) in the last 4 weeks, or daratumumab in the last 3 weeks.I have multiple myeloma, treated with specific therapies, and have seen improvement.I am fully active or restricted in physically strenuous activity but can do light work.I haven't taken targeted cancer drugs within the shortest period of 2 weeks or 5 half-lives before my apheresis collection.
- Group 1: PHE885 (Part A)
- Group 2: PHE885 (Part B)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the maximum number of participants for this clinical trial?
"This clinical trial requires 56 patients that meet the predetermined eligibility requirements. Those interested can enroll from a range of healthcare facilities, such as Medical College of Wisconsin in Milwaukee, WI and Beth Israel Deaconess Medical Centre KS121 in Boston, MA."
Are participants still being welcomed for this experiment?
"As indicated on clinicaltrials.gov, this medical study is currently seeking volunteers and has been open since July 23rd 2020 with the last update made on July 28th 2022."
Does PHE885 come with any significant safety risks?
"The safety of PHE885 is estimated at a level 1 on the scale due to its Phase 1 classification, indicating that there is minimal supporting evidence for both efficacy and safety."
Share this study with friends
Copy Link
Messenger